Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 20/20 | 1.00 |
| ▸ | GABRB3 | P28472 | 20/20 | 1.00 |
| ▸ | GABRA5 | P31644 | 20/20 | 1.00 |
| ▸ | GABRA3 | P34903 | 19/20 | 1.00 |
| ▸ | GABRA2 | P47869 | 19/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 18/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2646602 | 0.91 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA3GABRA2 | |
| SCHEMBL2645774 | 0.85 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA3GABRA2 | |
| SCHEMBL2647131 | 0.83 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA3GABRA2 | |
| SCHEMBL2647003 | 0.83 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA3GABRA2 | |
| SCHEMBL2646334 | 0.80 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA3GABRA2 | |
| SCHEMBL2646664 | 0.79 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA3GABRA2 | |
| SCHEMBL2652547 | 0.79 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA3GABRA2 | |
| SCHEMBL2646947 | 0.78 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA3GABRA2 | |
| SCHEMBL2654101 | 0.78 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA3GABRA2 | |
| SCHEMBL2647533 | 0.78 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA3GABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6174886-B1 | TREATMENT AND/OR PREVENTION OF PSYCHOTIC DISORDERS INCLUDING SCHIZOPHRENIA WITH REDUCED SEDATION; SELECTIVE LIGANDS FOR GAMMA-AMINOBUTYRIC ACID A RECEPTORS, IN PARTICULAR HAVING HIGH AFFINITY FOR THE ALPHA2 AND/OR ALPHA3 SUBUNIT | MERCK SHARP & DOHME LTD. (GB) | 2001-01-16 | — | — | US | claimed |
| US-6063783-A | Analgesic use of triazolo-pyridazine derivatives | MERCK SHARP & DOHME LTD. (GB) | 2000-05-16 | — | — | US | claimed |
| US-6046196-A | Antispastic use of triazolo-pyridazine derivatives | MERCK SHARP & DOHME LTD. (GB) | 2000-04-04 | — | — | US | claimed |
| US-6255305-B1 | PSYCHOLOGICAL DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 2001-07-03 | — | — | US | disclosed |
| US-6174886-B1 | TREATMENT AND/OR PREVENTION OF PSYCHOTIC DISORDERS INCLUDING SCHIZOPHRENIA WITH REDUCED SEDATION; SELECTIVE LIGANDS FOR GAMMA-AMINOBUTYRIC ACID A RECEPTORS, IN PARTICULAR HAVING HIGH AFFINITY FOR THE ALPHA2 AND/OR ALPHA3 SUBUNIT | MERCK SHARP & DOHME LTD. (GB) | 2001-01-16 | — | — | US | disclosed |
| US-6110915-A | Antiemetic use of triazolo-pyridazine derivatives | MERCK & CO., INC. (US) | 2000-08-29 | — | — | US | disclosed |
| US-6107296-A | Neuroprotective use of triazolo-pyridazine derivatives | MERCK SHARP & DOHME, LTD. (GB) | 2000-08-22 | — | — | US | disclosed |
| US-6063783-A | Analgesic use of triazolo-pyridazine derivatives | MERCK SHARP & DOHME LTD. (GB) | 2000-05-16 | — | — | US | disclosed |
| US-6046196-A | Antispastic use of triazolo-pyridazine derivatives | MERCK SHARP & DOHME LTD. (GB) | 2000-04-04 | — | — | US | disclosed |
| WO-1999025353-A1 | THERAPEUTIC USES OF TRIAZOLO-PYRIDAZINE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1999-05-27 | — | — | WO | disclosed |
| EP-0915875-A2 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 1999-05-19 | — | — | EP | disclosed |
| WO-1998004559-A2 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 1998-02-05 | — | — | WO | disclosed |